Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InflaRx (IFRX) Research & Development (2016 - 2026)

InflaRx's Research & Development history spans 9 years, with the latest figure at -$4.9 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 33.84% to -$4.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $33.4 million, a 331951.07% increase, with the full-year FY2025 number at $29.9 million, up 3569097.07% from a year prior.
  • Research & Development hit -$4.9 million in Q1 2026 for InflaRx, down from $53.8 million in the prior quarter.
  • Over the last five years, Research & Development for IFRX hit a ceiling of $53.8 million in Q4 2025 and a floor of -$15812.4 billion in Q1 2023.
  • Historically, Research & Development has averaged -$1377.2 billion across 5 years, with a median of -$8.0 million in 2023.
  • The widest YoY moves for Research & Development: up 516.96% in 2023, down 134538545.21% in 2023.
  • Tracing IFRX's Research & Development over 5 years: stood at -$8.5 million in 2022, then soared by 516.96% to $35.5 million in 2023, then fell by 14.24% to $30.4 million in 2024, then soared by 76.76% to $53.8 million in 2025, then tumbled by 109.08% to -$4.9 million in 2026.
  • Business Quant data shows Research & Development for IFRX at -$4.9 million in Q1 2026, $53.8 million in Q4 2025, and -$7.3 million in Q3 2025.